199 related articles for article (PubMed ID: 1788163)
41. Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits.
Fayyaz A; Ranta VP; Toropainen E; Vellonen KS; Ricci GD; Reinisalo M; Heikkinen EM; Gardner I; Urtti A; Jamei M; Del Amo EM
Mol Pharm; 2020 Feb; 17(2):588-594. PubMed ID: 31794668
[TBL] [Abstract][Full Text] [Related]
42. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
43. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
44. Light-dark variations in ocular timolol concentrations following topical solution instillation in the pigmented rabbit.
Ohdo S; Zhu J; Lee VH
Life Sci; 1992; 51(26):2025-31. PubMed ID: 1474859
[TBL] [Abstract][Full Text] [Related]
45. Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load.
Chang SC; Bundgaard H; Buur A; Lee VH
Invest Ophthalmol Vis Sci; 1987 Mar; 28(3):487-91. PubMed ID: 3557861
[TBL] [Abstract][Full Text] [Related]
46. The effect of pilocarpine on ocular levobunolol absorption from ophthalmic solutions.
Tang-Liu DD; Richman JB
J Ocul Pharmacol; 1994; 10(4):605-15. PubMed ID: 7714404
[TBL] [Abstract][Full Text] [Related]
47. Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation parameters.
Scholz M; Lin JE; Lee VH; Keipert S
J Ocul Pharmacol Ther; 2002 Oct; 18(5):455-68. PubMed ID: 12419096
[TBL] [Abstract][Full Text] [Related]
48. Influence of corneal epithelial integrity on the penetration of timolol prodrugs.
Chien DS; Bundgaard H; Lee VH
J Ocul Pharmacol; 1988; 4(2):137-46. PubMed ID: 3171338
[TBL] [Abstract][Full Text] [Related]
49. Decrease in corneal damage due to benzalkonium chloride by the addition of sericin into timolol maleate eye drops.
Nagai N; Ito Y; Okamoto N; Shimomura Y
J Oleo Sci; 2013; 62(3):159-66. PubMed ID: 23470443
[TBL] [Abstract][Full Text] [Related]
50. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol.
Chang SC; Chien DS; Bundgaard H; Lee VH
Exp Eye Res; 1988 Jan; 46(1):59-69. PubMed ID: 3342834
[TBL] [Abstract][Full Text] [Related]
51. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
Pellinen P; Huhtala A; Tolonen A; Lokkila J; Mäenpää J; Uusitalo H
Curr Eye Res; 2012 Feb; 37(2):145-54. PubMed ID: 22049909
[TBL] [Abstract][Full Text] [Related]
52. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
[TBL] [Abstract][Full Text] [Related]
53. Ocular drug interactions involving topically applied timolol in the pigmented rabbit.
Luo AM; Sasaki H; Lee VH
Curr Eye Res; 1991 Mar; 10(3):231-40. PubMed ID: 2044391
[TBL] [Abstract][Full Text] [Related]
54. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate.
Arnold JJ; Hansen MS; Gorman GS; Inoue T; Rao V; Spellen S; Hunsinger RN; Chapleau CA; Pozzo-Miller L; Stamer WD; Challa P
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1118-26. PubMed ID: 23307957
[TBL] [Abstract][Full Text] [Related]
55. Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits.
Kyyrönen K; Urtti A
J Pharm Sci; 1990 Aug; 79(8):688-91. PubMed ID: 2231330
[TBL] [Abstract][Full Text] [Related]
56. The effects of combination glaucoma medications on ocular surface epithelial cells.
Ammar DA; Kahook MY
Adv Ther; 2009 Oct; 26(10):970-5. PubMed ID: 19921496
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic basis for nonadditivity of intraocular pressure lowering in timolol combinations.
Lee VH; Luo AM; Li SY; Podder SK; Chang JS; Ohdo S; Grass GM
Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2948-57. PubMed ID: 1917398
[TBL] [Abstract][Full Text] [Related]
58. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].
Nenciu A; Stefan C; Ardelean C
Oftalmologia; 2004; 48(1):35-42. PubMed ID: 15279417
[TBL] [Abstract][Full Text] [Related]
59. Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment.
Araie M; Takase M; Sakai Y; Ishii Y; Yokoyama Y; Kitagawa M
Jpn J Ophthalmol; 1982; 26(3):248-63. PubMed ID: 6130180
[TBL] [Abstract][Full Text] [Related]
60. Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas.
Chetoni P; Burgalassi S; Monti D; Saettone MF
Toxicol In Vitro; 2003 Aug; 17(4):497-504. PubMed ID: 12849734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
